Amgen (NASDAQ:AMGN) and Kyowa Kirin (OTCPK:KYKOF) announced on Tuesday that their antibody therapy rocatinlimab is safe and ...

Data from the late-stage trial of amlitelimab weren’t as strong as the results seen in Phase 2, adding to doubts about a drug ...

The most effective treatments for eczema accomplish three things: They calm inflammation, bring relief from itch and restore ...

Shares in French drugmaker Sanofi fell more than 10% on Thursday, wiping nearly $13 billion off its market value, after ...

Amlitelimab has been billed by Sanofi as a successor to its Regeneron-partnered, $14.5 billion blockbuster Dupixent ...

Sanofi (NASDAQ:SNY) stock took a beating Thursday after its latest eczema drug trial left Wall Street unconvinced, even ...

Sanofi shares plunged after its experimental drug for the skin condition atopic dermatitis disappointed investors with a less ...

Sanofi (SNY) stock drops after Phase 3 trial results for amlitelimab, its experimental therapy for eczema, disappointed ...

Enveda has closed its second $150 million financing round of the year. The series D round, which moves Enveda’s total funding ...